It has ruined millions of lives across the globe and even spawned a massively popular TV show called Dopesick starring Michael Keaton - but now the shocking saga may have come to an end. A U.S. bankruptcy judge has agreed to endorse Purdue Pharma’s latest restructuring plan, clearing the way for a settlement that will approach nearly C$10 billion and draw heavily on the personal wealth of the Sackler family rather than on any insurance contribution.
The ruling, delivered Friday by Judge Sean Lane, brings Purdue’s winding six-year insolvency towards its conclusion and unlocks long-awaited funding for governments and individuals seeking compensation for the drugmaker’s role in the opioid crisis. The judge said he would release a full explanation early next week.
The agreement, first outlined in January, represents an increase of more than US$1-billion from an earlier proposal rejected by the U.S. Supreme Court last year. That prior version would have protected members of the Sackler family from future civil lawsuits, a provision the court found was not supported by bankruptcy law. In the new arrangement, claimants preserve the ability to sue family members who do not opt in to the settlement.
Purdue sought bankruptcy protection in 2019 as lawsuits mounted across the United States alleging the company and its owners had aggressively promoted OxyContin while minimising its addiction risks. Steve Miller, Purdue’s board chair, said on Friday that “today cements the end of a long chapter, and brings us very near to the end of the book for Purdue.” He added that the plan “unlocks billions in recoveries and significant non-monetary benefits.”
As part of the deal, the Sacklers will relinquish ownership and contribute between US$6.5-billion and US$7-billion — roughly C$8.8-billion to C$9.5-billion — while a newly formed non-profit, Knoa Pharma, will assume control of Purdue’s operations. Mr. Miller described the restructured company as a “purpose-driven” entity intended to support efforts to address opioid addiction.
The opioid crisis has been connected to 900,000 deaths in the United States since 1999. Purdue, through OxyContin, became one of the most recognisable corporate names linked to the epidemic. Hundreds of state, local and tribal governments, along with individual victims, supported the restructuring agreement. More than 99 per cent of creditors voted in favour.
Individual claimants are slated to receive up to US$865-million (approximately C$1.17-billion), although the amounts will vary depending on documentation and the length of opioid prescriptions. State and local governments will be the primary beneficiaries of the rest of the funds, expected to be used over the next decade and a half for treatment, prevention and recovery initiatives.
For insurers watching the proceedings, one feature remains conspicuous: the absence of any material insurance participation in the payout. Allegations against Purdue centred on misleading marketing and failure to disclose addiction risks — conduct that generally activates intentional-acts and fraud exclusions in liability and directors’ and officers’ policies. Neither court filings nor the settlement plan indicate insurer contributions, consistent with a broader trend in which opioid-related manufacturer liabilities have been deemed uninsurable.
The reorganisation comes after years of contentious legal battles, intense public scrutiny and shifting strategies among plaintiffs. While several individuals expressed dissatisfaction during recent hearings — including concerns about limited direct compensation or lack of criminal sanctions — they represented only a small fraction of those involved. Out of more than 54,000 personal-injury voters, just 218 rejected the plan.
California Attorney General Rob Bonta, whose state joined 54 others in supporting the settlement, said earlier this year that “by holding Purdue Pharma and the Sackler family accountable for their role in fueling the opioid epidemic, we're bringing much-needed funds for addiction treatment, prevention, and recovery to those impacted by this crisis.”
The final administrative steps now proceed toward completion, and Knoa Pharma could launch as early as 2026. Governments will receive funds over a period of up to 15 years, while individual payments are expected in the coming year.
For the insurance industry, the Purdue settlement stands as a pointed example of the limits of coverage for mass-tort exposures where allegations of deliberate misconduct dominate the record. The case also reinforces a reality already shaping underwriting in both Canada and the United States: that opioid manufacturer liability has effectively migrated outside the domain of insurable risk, leaving corporate balance sheets — and, in this case, family wealth — to shoulder the burden.
Canada has not been immune to the opioid crisis that originated, in part, from the same prescribing and marketing practices at the centre of the U.S. litigation against Purdue Pharma. Although the legal actions have unfolded largely south of the border, OxyContin and its reformulated successor, OxyNEO, were widely dispensed in Canada during the 2000s and early 2010s. Provinces and territories have since faced rising health-care, social-services and law-enforcement costs tied to opioid misuse, accidental overdoses and long-term addiction treatment.
Canadian jurisdictions pursued their own claims against opioid manufacturers and distributors. In 2018, British Columbia launched the first government lawsuit aimed at recovering public-health costs associated with opioid-related harm; several provinces later joined the action or filed parallel suits. The federal government backed provincial efforts through legislative amendments allowing cost-recovery actions modelled on earlier tobacco litigation.
Purdue Canada, a separate but related corporate entity, has been a named defendant in multiple Canadian proceedings. The company agreed in 2022 to a C$150-million national class-action settlement for consumers and governments related to the marketing of opioid medications. That agreement remains distinct from the much larger U.S. bankruptcy plan and does not give Canadian claimants access to the American settlement funds.
Canada continues to grapple with one of the highest per-capita rates of opioid deaths in the world. Public-health authorities have noted that the crisis is now driven primarily by illicit fentanyl and its analogues, yet the earlier period of widespread prescription opioid use is widely considered a contributing factor to current patterns of dependency. For policymakers, insurers and health-care systems, the U.S. settlement underscores the scale of financial exposure tied to pharmaceutical-driven public-health harms — and highlights gaps in Canada’s own frameworks for mass-tort cost recovery and the insurability of opioid-related liabilities.
